ESCO2 and neoplasm: Consistent with the esco2 haploinsufficient results, heterozygous loss of sgo1 resulted in statistically significant accelerated tumor onset in a p53 heterozygous background (Fig 3D, T50 = 422 days in the sgo1Δ8/+; p53+2/+ cohort vs. 478 days in the p53+2/+ cohort; p <0.0001 based on Log-rank test).